Relmada Therapeutics Inc (NAS:RLMD)

$ 3.11 0.02 (0.65%) Market Cap: 93.84 Mil Enterprise Value: 9.63 Mil PE Ratio: 0 PB Ratio: 1.30 GF Score: 29/100

Q1 2024 Relmada Therapeutics Inc Earnings Call Transcript
May 08, 2024

$3.83 (+0.26%)

Earnings
Q4 2023 Relmada Therapeutics Inc Earnings Call Transcript
Mar 19, 2024

$5.37 (-2.72%)

Earnings
Q3 2023 Relmada Therapeutics Inc Earnings Call Transcript
Nov 08, 2023

$3 (-1.64%)

Earnings
Q2 2023 Relmada Therapeutics Inc Earnings Call Transcript
Aug 08, 2023

$2.54 (-3.79%)

Earnings
Relmada Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript
Jun 14, 2023
Relmada Therapeutics Inc at Jefferies Healthcare Conference Transcript
Jun 08, 2023
Q1 2023 Relmada Therapeutics Inc Earnings Call Transcript
May 11, 2023

$3.17 (-3.06%)

Earnings
Q4 2022 Relmada Therapeutics Inc Earnings Call Transcript
Mar 23, 2023

$2.32 (-0.85%)

Earnings
Relmada Therapeutics Inc Top-line Results from Phase 3 RELIANCE I Trial for REL-1017 as an Adjunctive Treatment for Major Depressive Disorder - Corporate Call Transcript
Dec 07, 2022
Q3 2022 Relmada Therapeutics Inc Earnings Call Transcript
Nov 10, 2022

$5.84 (+1.39%)

Earnings
Q2 2022 Relmada Therapeutics Inc Earnings Call Transcript
Aug 11, 2022

$27.82 (-4.99%)

Earnings
Relmada Therapeutics Inc at Goldman Sachs Global Healthcare Conference Transcript
Jun 14, 2022
Q1 2022 Relmada Therapeutics Inc Earnings Call Transcript
May 05, 2022

$22.4 (-7.70%)

Earnings
Q4 2021 Relmada Therapeutics Inc Earnings Call Transcript
Mar 23, 2022

$23.33

Earnings
Relmada Therapeutics Inc Results of Human Abuse Potential Study of REL-1017 vs. Ketamine - Corporate Call Transcript
Feb 23, 2022
Q3 2021 Relmada Therapeutics Inc Earnings Call Transcript
Nov 11, 2021

$25.66 (+3.22%)

Earnings
Relmada Therapeutics Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 10, 2021
Q2 2021 Relmada Therapeutics Inc Earnings Call Transcript
Aug 10, 2021

$23 (+1.28%)

Earnings
Relmada Therapeutics Inc REL-1017 Clinical Data Update Call Transcript
Jul 27, 2021
Q1 2021 Relmada Therapeutics Inc Earnings Call Transcript
May 12, 2021

$33.61 (-3.81%)

Earnings
Q4 2020 Relmada Therapeutics Inc Earnings Call Transcript
Mar 23, 2021

$34.34 (-3.40%)

Earnings

Relmada Therapeutics Inc Top-line Results from Phase 3 RELIANCE I Trial for REL-1017 as an Adjunctive Treatment for Major Depressive Disorder - Corporate Call Transcript

Dec 07, 2022 / 10:00PM GMT

Release Date Price: $4.16 (-0.95%)

Transcript

Operator

Greetings. Welcome to the Relmada Therapeutics results of registrational Phase III RELIANCE I trial for REL-1017 as an adjunctive treatment for major depressive disorder.

(Operator Instructions)

Please note, this conference is being recorded. And I will now turn the conference over to your host Timothy McCarthy of LifeSci Advisors, you may begin.

Timothy McCarthy

LifeSci Advisors, LLC - MD & Relationship Manager

Thank you, Shomali, and thank you all for joining us this afternoon. With me on today's call are Relmada's Chief Executive Officer; Sergio Traversa; Maged Shenouda, Relmada's Chief Financial Officer; Dr. Paolo Manfredi, Relmada's Chief Scientific Officer; and RELIANCE Program Principal Investigator, Dr. Maurizio Fava, the Chairman of Harvard's Psychiatry Department.

Please note that certain information discussed on the call today is covered under the safe harbor provisions of the Private Securities Litigation Reform Act. We caution listeners that during this call, Relmada's management team will be making forward-looking

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.